CDMO Partnership Reimagined – Novartis Contract Manufacturing
To ensure the development and reliable supply of medicines to patients around the world, pharmaceutical and biotech companies increasingly rely on CDMOs, their capabilities and their output. How do you choose an outsourcing partner that will meet your high expectations, not only in the short term, but throughout the lifetime of your product? Read more here, and watch our video to learn what makes Novartis Contract Manufacturing different.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
